{"id":"W2099562503","doi":"10.1200/jco.2009.22.1077","title":"Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada); Saskatchewan Cancer Agency; McMaster University; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Amgen; Queen's University; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Epirubicin; Cyclophosphamide; Breast cancer; Internal medicine; Febrile neutropenia; Hazard ratio; Fluorouracil; Chemotherapy; Doxorubicin; Gastroenterology; Oncology; Cancer; Neutropenia; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034867,0.0006291889,0.001978236,0.000357469,0.0001470754,0.0004235763,0.0006434197,0.0008703579,0.002358249],"category_scores_gemma":[0.002843625,0.0002957021,0.002458509,0.0002788861,0.0005235104,0.0004229719,0.0002913976,0.001406118,0.0002710143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005157645,"about_ca_system_score_gemma":0.0006663441,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005155244,"about_ca_topic_score_gemma":0.00103285,"domain_scores_codex":[0.9982483,0.001213485,0.0001197417,0.0001328825,0.0000926174,0.0001929815],"domain_scores_gemma":[0.9980904,0.0009571552,0.0004624255,0.0001292216,0.00005142733,0.0003092578],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9658938,0.004683004,0.001718839,0.0003065128,0.001072034,0.00002754803,0.00001989296,0.0008896316,0.002536388,0.00008057354,0.000216371,0.02255547],"study_design_scores_gemma":[0.3829967,0.5894026,0.01531926,0.0000864821,0.003063047,0.0001304102,0.00003972075,0.003292533,0.004482879,0.0003769017,0.0007887232,0.00002074632],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959642,0.001995009,0.0003749567,0.0001622463,0.000152439,0.0005646878,0.0001965471,0.0000270028,0.000562904],"genre_scores_gemma":[0.9970366,0.0007783481,0.0005644315,0.0001828407,0.0001622722,0.0004933709,0.0002190876,0.000004291847,0.0005588367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0034867,"threshold_uncertainty_score":0.01843959,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04116585421662357,"score_gpt":0.4040302561459826,"score_spread":0.3628644019293591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}